Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NIPAL4-DT (NIPAL4 divergent transcript) refers to a non-coding RNA transcript at the NIPAL4 locus. According to Genecards, NIPAL4-DT is classified as an RNA gene and not as a protein-coding gene, enzyme, transporter, receptor, or other canonical therapeutic target family. There is no evidence it encodes a functional protein or acts as a direct therapeutic target, nor are any diseases, drugs, or biomarkers associated with it. The main gene at this locus, NIPAL4, is a membrane protein involved in epidermal lipid metabolism and autosomal recessive congenital ichthyosis[3]. However, NIPAL4-DT itself is a divergent transcript, presumed non-coding, and is not described as a target of therapeutic, diagnostic, or research interest.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NIPAL4 divergent transcript (NIPAL4-DT).